Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger

[Pelican Press 0]

This is the hidden content, please

• Sign In
• or
• Sign Up

Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger

If you’re not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an eye out for. One common approach is to try and find a company with returns on capital employed (ROCE) that are increasing, in conjunction with a growing amount of capital employed. Ultimately, this demonstrates that it’s a business that is reinvesting profits at increasing rates of return. Speaking of which, we noticed some great changes in Abbott Laboratories’ (NYSE:ABT) returns on capital, so let’s have a look.

Just to clarify if you’re unsure, ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested in its business. The formula for this calculation on Abbott Laboratories is:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets – Current Liabilities)

0.12 = US$7.1b ÷ (US$74b – US$15b) (Based on the trailing twelve months to December 2024).

Thus, Abbott Laboratories has an ROCE of 12%. That’s a relatively normal return on capital, and it’s around the 11% generated by the Medical Equipment industry.

This is the hidden content, please

• Sign In
• or
• Sign Up

NYSE:ABT Return on Capital Employed February 14th 2025

Above you can see how the current ROCE for Abbott Laboratories compares to its prior returns on capital, but there’s only so much you can tell from the past. If you’d like, you can

This is the hidden content, please

• Sign In
• or
• Sign Up

for free.

Abbott Laboratories’ ROCE growth is quite impressive. Looking at the data, we can see that even though capital employed in the business has remained relatively flat, the ROCE generated has risen by 45% over the last five years. So it’s likely that the business is now reaping the full benefits of its past investments, since the capital employed hasn’t changed considerably. On that front, things are looking good so it’s worth exploring what management has said about growth plans going forward.

To bring it all together, Abbott Laboratories has done well to increase the returns it’s generating from its capital employed. And investors seem to expect more of this going forward, since the stock has rewarded shareholders with a 63% return over the last five years. Therefore, we think it would be worth your time to check if these trends are going to continue.

On a separate note, we’ve found

This is the hidden content, please

• Sign In
• or
• Sign Up

you’ll probably want to know about.

While Abbott Laboratories may not currently earn the highest returns, we’ve compiled a list of companies that currently earn more than 25% return on equity. Check out this free

This is the hidden content, please

• Sign In
• or
• Sign Up

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

This is the hidden content, please

• Sign In
• or
• Sign Up

#Abbott #Laboratories #NYSEABT #Makings #MultiBagger

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up